

Inter-platelet communication driving thrombus formation is regulated by extracellular calpain-1 cleavage of connexin 62

Article

Published Version

Creative Commons: Attribution 4.0 (CC-BY)

Open Access

Taylor, K. A. ORCID: <https://orcid.org/0000-0002-4599-7727>, Elgheznawy, A., Adiyaman, R., Horn, T. L., Parkes, S., Hughes, C. E. ORCID: <https://orcid.org/0000-0002-9790-5820>, McGuffin, L. J. ORCID: <https://orcid.org/0000-0003-4501-4767> and Gibbins, J. M. ORCID: <https://orcid.org/0000-0002-0372-5352> (2025) Inter-platelet communication driving thrombus formation is regulated by extracellular calpain-1 cleavage of connexin 62. *Haematologica*, 110 (8). 286466. ISSN 1592-8721 doi: 10.3324/haematol.2024.286466 Available at <https://centaur.reading.ac.uk/121579/>

It is advisable to refer to the publisher's version if you intend to cite from the work. See [Guidance on citing](#).

To link to this article DOI: <http://dx.doi.org/10.3324/haematol.2024.286466>

Publisher: Ferrata Storti Foundation

All outputs in CentAUR are protected by Intellectual Property Rights law, including copyright law. Copyright and IPR is retained by the creators or other copyright holders. Terms and conditions for use of this material are defined in the [End User Agreement](#).

www.reading.ac.uk/centaur

CentAUR

Central Archive at the University of Reading

Reading's research outputs online

Inter-platelet communication driving thrombus formation is regulated by extracellular calpain-1 cleavage of connexin 62

Kirk A. Taylor,* Amro Elghezawy,* Recep Adiyaman, Tyler L. Horn, Sarah Parkes, Craig E. Hughes, Liam J. McGuffin and Jonathan M. Gibbins

Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK

*KAT and AE contributed equally as first authors.

Correspondence: J.M. Gibbins
j.m.gibbins@reading.ac.uk

Received: August 19, 2024.

Accepted: February 25, 2025.

Early view: March 6, 2025.

<https://doi.org/10.3324/haematol.2024.286466>

©2025 Ferrata Storti Foundation

Published under a CC BY license 

Abstract

Connexin (Cx) gap junction proteins are expressed by a multitude of cells and function as plasma membrane hemichannels or dock to form intercellular communication tunnels. Whilst Cx43 has garnered considerable attention, less is known about the structure and function of Cx62 channels. Platelets and megakaryocytes express Cx37, Cx40 and Cx62, which contribute to hemostatic and thrombotic responses. Our study explores an unexpected finding that following platelet activation, an extracellular region of Cx62 undergoes proteolytic cleavage by calpain-1. We adopted an interdisciplinary approach to evaluate structural and functional consequences of calpain-mediated cleavage of Cx62. Cellular signaling was assayed by immunoblotting, aggregation and calcium flux assays. Gap junction function and thrombus formation were assessed under arteriolar flow. *In silico* modeling was used to predict calpain-mediated changes to the pore diameter and design a decoy peptide (⁶²Pept-NT). Mechanistically, Cx62 cleavage is Ca²⁺-dependent and requires calpain-1 externalization. Modeling a predicted calpain-1 cleavage site on the first extracellular loop, shows that calpain can dock to Cx62 monomers, promoting stepwise channel cleavage. Consequently, we predict a significant pore dilation enhancing diffusion of signaling molecules between cells and into the extracellular milieu. We designed a decoy peptide that abrogated calpain-1-mediated cleavage, reduced intercellular communication and restricted thrombus growth. Cx62 cleavage was dependent upon sequential action of protein kinase A, protein phosphatase 2A and Ca²⁺ release from intracellular stores. Extracellular calpain cleavage represents a fundamentally new regulatory mechanism for Cx62, culminating in an irreversible open state.

Introduction

Platelet activation and occlusive thrombus formation underpins the etiology of myocardial infarction and ischemic stroke. These cells store and release over 300 bioactive molecules and that regulate angiogenesis, proliferative responses, necrosis, proteolysis and inflammation.¹⁻³ The importance of platelets beyond cardiovascular disease is garnering increasing attention within the arenas of cancer biology and inflammatory responses.⁴⁻⁶ Connexin gap junctions and pannexin-1 are critically important in health and disease.⁷ Aberrant activation of connexins and channel-specific mutations are associated with cancers, cardiovascular disease and neurological complications.⁷⁻⁹ Given the global burden of these conditions on patients and healthcare

systems, there is mounting interest in developing therapeutic approaches and drugs to target connexins, which have centered on connexin 43 (Cx43), due to its ubiquitous expression profile. Strategies have included mimetic peptides, channel modulators and repurposing of existing drugs (e.g. carbenoxolone).^{10,11} However, given that connexins are broadly distributed, it is important to look beyond Cx43 and further our understanding of the structure and function of other family members. Thus, providing critical groundwork for the rational design of connexin-specific therapies using gene editing and small molecule approaches. Connexins are synthesized and assemble into hexameric hemichannels that are trafficked to the plasma membrane, where they function as hemichannels or can dock with opposing channels to form gap junctions.¹² This dual role

enables connexins to serve as conduits for the exchange of small molecules between the cytosol and extracellular milieu to directly convey intercellular signals.¹³ Connexins are considered to be non-selective channels that facilitate passage of molecules ≤1 kDa in size. Therefore, enabling the release or transfer of bioactive molecules, such as ATP, Ca²⁺, inositol-1,4,5-trisphosphate and micro RNA.^{13,14} Connexins are sub-divided into five families (α, β, γ, δ and ε) and three members of the α-connexin family have been identified in platelets: Cx37, Cx40 and Cx62.^{15,16} Targeted inhibition of Cx37, Cx40 or Cx62 reduces thrombotic responses in an *in vivo* murine model. Gap junction blockers also reduce Ca²⁺ responses, platelet aggregation and thrombus formation *in vitro*, highlighting their importance in coordinating platelet responses.^{17,18} While research into the roles and regulation of Cx37 and Cx40 have been studied in a range of cell types, we were first to report functional expression of *GJA10* (Cx62 in human and Cx57 in mouse).¹⁸ The platelet therefore presents itself as a useful tool for the assessment of Cx62 function providing insights into the role of this channel in relevant cell types and disease models. Mechanisms underpinning the regulation of gap junction function have been explored with roles for phosphorylation, proteolytic cleavage, ubiquitination and sumoylation.¹⁹ We recently demonstrated that platelet Cx62 is regulated by protein kinase A (PKA) in a cAMP-independent manner.¹⁸ In the present study, we sought to further explore the regulation and function of Cx62 in human platelets. We made the surprising discovery that upon platelet stimulation, Cx62 channels are subject to Ca²⁺-dependent proteolytic cleavage, likely via calpain-1. *In silico* modeling reveals that calpain-1-mediated cleavage substantially increases the Cx62 pore diameter, and our functional data report increased diffusion of the cytosolic dye calcein. This process was regulated by the sequential action of protein kinase A (PKA), protein phosphatase 2A (PP2A) and elevation of intracellular Ca²⁺.

Methods

Additional methods are provided in the *Online Supplementary Appendix*.

Reagents

PGI₂, thrombin, calpeptin and EDTA (ethylenediaminetetraacetic acid) were purchased from Sigma-Aldrich (Poole, UK). TRAP6, collagen and cross-linked collagen-related peptide (CRP) were supplied by Bachem (Bubendorf, Switzerland), Takeda (Linz, Austria) and CambColl (Cambridge, UK), respectively. Custom peptides listed in Table 1 were synthesized by Sigma-Aldrich. Fura2-AM and calcein-AM were from Thermo Fisher (Loughborough, UK). 5,5'-dimethyl-Bapta, AM ester was from Sartorius (Beit HaEmek, Israel) and LB-100 was from SelleckChem (Cambridge, UK). Recombinant calpain was purchased from Scientific

Laboratory Supplies (Nottingham, UK). Unless specified, all other reagents were from Sigma-Aldrich.

Platelet isolation

This study was approved by the University of Reading Research Ethics Committee. Blood was collected from healthy human donors, who had abstained from anti-platelet medication for a minimum of 2 weeks, after informed consent in accordance with the declaration of Helsinki. Blood was collected into Na-citrate vacutainers (3.8%) and centrifuged to obtain platelet-rich plasma (PRP, 100 xg, 20 minutes [min]).²⁰ Washed platelets were collected by centrifugation (900 xg, 7 min) and re-suspended into Ca²⁺-free Tyrode's-HEPES buffer (134 mM NaCl, 0.34 mM Na₂HPO₄, 2.9 mM KCl, 12 mM NaHCO₃, 20 mM N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, 5 mM glucose and 1 mM MgCl₂, pH 7.3) at a concentration of 4x10⁸ platelets mL⁻¹ and rested for 30 min at 30°C before use.

In silico modeling of interactions between Cx62 and calpain-1

In our previous study¹⁸ we modeled Cx62 and its interaction with the mimetic peptide, we initially predicted the Cx62 monomer using the IntFOLD server.²¹ Subsequently, we built the Cx62 hemichannel by utilizing the crystal structure of Cx26 as a template. Then, the Swisdock webserver was also employed to dock the mimetic peptide to Cx62 monomer, generating alternative conformations to predict the peptide binding site and their interactions.²² With the development of AlphaFold2, advanced neural network-based tools can predict protein-protein, and protein-peptide structures at high accuracy without the need for additional docking tools and the explicit usage of crystal structures.²³ Consequently, our *in silico* pipeline underwent a significant upgrade with the development of MultiFOLD, specifically designed to predict protein-protein, protein-peptide interactions, and multimeric states.²⁴ Firstly, we excluded from the model the long-disordered region within C-terminus based on DISOPRED3 server prediction to focus on the functional sites.²⁵ Then, the Cx62 monomer and its interacting partners, including the decoy peptide and calpain-1, were modeled using MultiFOLD.²⁴ Additionally, various combinations of Cx62 hemichannel and its cleavage were also modeled without the need for explicit crystal structures, utilizing MultiFOLD's capability to accurately predict the multimeric state.

Table 1. Custom peptides for the study of Cx62 function.

Peptide name	Sequence (NH ₂ -COOH)
⁶² Gap27	SRPTEKTIFML
^{Scr} Gap27	REPTISFMKLT
⁶² Pept-NT	DEQSAFACNTRQPG
^{Scr} Pept-NT	SECQFQGPTAADRN

Statistics

Data are expressed as mean $\pm$ standard error of the mean. Statistical evaluation was performed using Student's *t* test for paired data or one-way ANOVA with Bonferroni post-test for repeated measures, as indicated in the figure legends. Statistical significance is denoted as not significant (NS), *, ** or *** for $P > 0.05$, $P < 0.05$, $P < 0.01$ or $P < 0.001$, respectively.

Results

Cx62 is a calpain substrate in activated platelets

In our previous study of platelet Cx62 we noticed that there was a loss of immunoreactivity following stimulation by platelet agonists. We explored this phenomenon further by performing immunoblotting experiments. Stimulation of platelets by thrombin or collagen led to a significant reduction of intact Cx62 (Figure 1A). Interestingly, decreased immunoreactivity was accompanied by the appearance of a second smaller band below 37 kDa (Figure 1B). Cx62 cleavage also took place following exposure of platelets with supraphysiological levels of Ca^{2+} (5 mM), indicating that this was a Ca^{2+} -mediated process (Figure 1B, C). Cleavage of Cx62 was concentration-dependent with thrombin concentrations ≥ 0.03 units mL^{-1} or collagen concentrations ≥ 1 $\mu\text{g mL}^{-1}$, sufficient to induce platelet activation (*Online Supplementary Figure S1*). We also explored whether other platelet connexins are subject to Ca^{2+} -dependent proteolytic modification. Our experiments

revealed a similar phenomenon for Cx40, which underwent proteolytic cleavage following stimulation by the Ca^{2+} ionophore ionomycin (*Online Supplementary Figure S2*). Stimulation of platelets by thrombin or collagen leads to a rapid increase of intracellular Ca^{2+} mediated by release from intracellular stores and activation of plasma membrane ion channels.²⁶⁻²⁸ We studied the Ca^{2+} -dependence of Cx62 cleavage through chelation of extracellular or intracellular Ca^{2+} . Chelation of extracellular Ca^{2+} by EGTA (Figure 2A) or intracellular Ca^{2+} by BAPTA-AM (Figure 2B) protected against proteolytic cleavage of Cx62. Ca^{2+} -dependent proteolysis of Cx32 and Cx50 has been shown to be mediated by calpain in hepatocytes and lens fiber cells.^{29,30} Calpain activation can be detected by immunoblot with an electrophoretic shift from its inactive (78 kDa) to active (76 kDa) conformation.³¹ Probing our blots for calpain-1 isoforms, we noted that activation of calpain-1 coincided with the cleavage of Cx62 (Figure 2). We therefore examined whether calpain-1 activity was required to achieve cleavage of Cx62. The calpain-1 inhibitor calpeptin protected against agonist-evoked Cx62 cleavage, pointing to a role for this protease (Figure 2C). These data point to a mechanism for post-activation regulation of Cx62 by a Ca^{2+} -dependent protease and the involvement of calpain-1.

Cx62 has an extracellular calpain-1 cleavage site that regulates intercellular communication

We next adopted an *in silico* approach to search for poten-




Figure 1. Cx62 is post-translationally modified in activated human platelets. (A) Representative immunoblot showing a reduction of full-length Cx62 expression by resting platelets (Veh) or following stimulation by thrombin (Thr; 0.03 U mL^{-1} , 5 minutes [min]) or collagen (Coll; 1 $\mu\text{g mL}^{-1}$, 5 min), N=7 per group. (B) Stimulation of platelets by thrombin, collagen or extracellular Ca^{2+} (5 mM, 15 min) resulted in the appearance of a smaller cleavage product close to 37 kDa. (C) Cx62 occurs at early time points with cleavage products detected at 50 seconds onwards. Arrows indicate the cleavage fragment of Cx62 and β actin was used as a loading control. Data were analyzed by one-way ANOVA and not significant (NS), ** or *** denote $P > 0.05$, $P < 0.01$, $P < 0.001$, respectively. Cx: connexin.

tial calpain-1 cleavage sites within the Cx62 sequence. We utilized an open-source calpain-1 cleavage site prediction program (GPS-CCD) to identify and score calpain-1 cleavage sites. This approach predicted a calpain-1 cleavage site within the first extracellular loop (DEQSAFACNTRQPG), with a score of 0.693, which exceeded the threshold of 0.654. We previously developed a model of Cx62 within IntFOLD based on the crystal structure of Cx26.^{18,21} To enhance understanding, an advanced computational pipeline was utilized to model the interaction between Cx62, calpain-1, the decoy peptide, and Cx62 hemichannel. Using our model, we highlighted the predicted calpain cleavage site on a Cx62 monomer (Figure 3A, yellow). Models of calpain-1 docking onto a Cx62 monomer show interactions between the catalytic region of calpain-1 and the predicted cleav-

age site (Figure 3B). We further tested our hypothesis by modeling interactions between calpain-1 and a hexameric Cx62 hemichannel (Figure 3C). These data show that whilst calpain-1 can dock onto a Cx62 hemichannel, it is unlikely that multiple calpain-1 enzymes can interact with the connexin simultaneously. We therefore predict that calpain-1 cleaves Cx62 channels in a stepwise manner. Finally, we modeled the structural consequence of calpain cleavage upon the pore structure of Cx62. Prior to calpain cleavage the Cx62 channel has a minimum pore diameter of 12.5 Å (reference molecules glucose, ATP and albumin are predicted to have diameters of 9 Å, 14 Å and 30 Å, respectively; Figure 3D). Removal of the cleaved region of Cx62 results in a substantial increase of minimum pore diameter to 29.5 Å (Figure 3E).




Figure 2. Cx62 is a calpain substrate in activated human platelets. Effect of EGTA: (A) 5 mM, 5 minutes (min), (B) BAPTA-AM (20 μ M, 30 min) or (C) calpeptin (50 μ M, 30 min) upon detection of full-length Cx62 and calpain-1 activation. Comparisons were drawn between unstimulated (Unstim.) platelets and those stimulated by thrombin (Thr; 0.03 U mL⁻¹, 5 min) or collagen (Coll; 1 μ g mL⁻¹, 5 min). Data are representative of 3 independent experiments and were analyzed by one-way ANOVA. Not significant (NS) or * denote $P > 0.05$ or $P < 0.05$, respectively. Cx: connexin.

Our model predicts that calpain acts on an extracellular site. Notably, calpain release from endothelial cells, lymphocytes, osteoblasts and chondrocytes has been reported.^{32,33} Calpain release may occur through active secretion or leak from apoptotic cells.³⁴ Released calpain modulates endothelial cell protease-activated receptor function.³⁵ Thus, we investigated whether calpain-1 can be detected in platelet releasate and whether we could interrupt calpain-1-mediated cleavage. We prepared supernatants from platelets stimulated by thrombin or collagen and ran immunoblots for calpain-1 and Cx62. Consistent with previous studies, we detected active calpain-1 isoforms in the releasate of platelets stimulated by thrombin or collagen (Figure 4A). To evaluate the functional role of calpain-1 cleavage upon Cx62, we designed a calpain-1 decoy peptide (⁶²Pept-NT; DEQSAFACNTRQPG) based upon the predicted cleavage sequence within Cx62. We also designed a control peptide from a scrambled sequence of the same residues (^{Scr}Pept-NT; SECQFQGPTAADRN). Modeling these peptides suggests that the decoy, but not scrambled control, peptide is able to bind to the catalytic region of calpain-1 (*Online Supplementary Figure S3*). This peptide protected against Cx62 cleavage by calpain-1, despite clear activation of the protease (Figure 4B). The decoy peptide did not affect cleavage of the intracellular calpain target talin-1 (*Online Supplementary Figure S4*). Similar findings were observed when platelets were stimulated by TRAP6 (PAR1 agonist) or collagen-related peptide (CRP; GPVI agonist; *Online Supplementary Figure S5*). To assess whether extracellular calpain was sufficient to induce Cx62 cleavage, we evaluated the effect of exogenous calpain applied to unstimulated platelets. Application of active calpain in the presence of extracellular Ca²⁺ for up to 1 hour failed to induce cleavage of Cx62 (*Online Supplementary Figure S6*). These data suggest that either calpain-mediated cleavage of Cx62 requires platelet activation and conformational change of the channel, or that there is insufficient protein at the surface in resting platelets.

It is unclear whether calpain-1-mediated cleavage of Cx62 represents a primary activation pathway for the channel, or if it may be a mechanism to prevent channel closure. We have shown that selective inhibition of Cx62 leads to a reduction of thrombin- and collagen-evoked platelet aggregation.¹⁸ However, pre-incubation of platelets with our decoy peptide did not lead to a reduction of platelet aggregation responses (*Online Supplementary Figure S3B*), indicating that calpain-1 cleavage is not essential for primary activation of Cx62. We next studied the impact of calpain cleavage upon thrombus formation under arteriolar shear (1,000 s⁻¹) in an endpoint *ex vivo* assay. Imaging of fixed thrombi revealed that inhibition of calpain cleavage did not affect platelet adhesion to collagen as surface coverage values were comparable between groups (Figure 4C). Importantly, decoy of calpain cleavage by ⁶²Pept-NT reduced thrombus height and volume (Figure 4D-F), consistent with




Figure 3. Structural consequences of calpain-mediated cleavage of Cx62 channels. (A) Cx62 monomer shown in green with the predicted calpain-1 cleavage site (DEQSAFACNTRQPG) mapped in yellow. Side (i) and 90° rotation showing extracellular aspect (ii) are shown. (B) Docking of calpain-1 (cyan) to a Cx62 monomer. Side (i) and 90° rotation showing extracellular aspect (ii) are shown. (C) Docking of calpain-1 to a Cx62 hemichannel (green). Side (i) and 90° rotation showing extracellular aspect (ii) are shown. (D) View through intact Cx62 channel pore from intracellular aspect with a minimum internal diameter of 12.5 Å (ii). (E) View through cleaved Cx62 channel pore from intracellular aspect. Cleavage increases the minimum pore diameter from 12.5 Å to 29.5 Å (ii). All images were rendered using PyMOL (<http://www.pymol.org/pymol>). Cx: connexin.

a role for calpain-mediated cleavage in regulating thrombus formation. Given that calpain cleavage influenced thrombus formation but not aggregation responses, we explored whether Cx62 influences clot structure by thromboelastography. In our assay, whole blood was pre-incubated with a generic gap junction blocker (carbenoxolone, Cbx) or the calpain decoy peptide $^{62}\text{Pept-NT}$ prior to clot for-

mation. Inhibition of connexins delayed the onset of clot formation and reduced the maximum amplitude, indicating reduced clot strength (*Online Supplementary Figure S7*). A smaller impact on the time to initiation of clot formation was observed in the presence of the calpain decoy peptide (*Online Supplementary Figure S7*). Overall, there was a trend towards reduced clot strength, but it is not likely




Figure 4. The calpain decoy peptide $^{62}\text{Pept-NT}$ protects against cleavage of Cx62, restricts thrombus growth and reduces gap junction activity. (A) The detected levels of active calpain in platelet releasate in the presence or absence of thrombin (Thr; 0.03 U mL^{-1} , 5 minutes [min]) or collagen (Coll; 1 $\mu\text{g mL}^{-1}$, 5 min). (B) Effects of $^{62}\text{Pept-NT}$ on calpain active form levels and Cx62 modifications in platelets stimulated by Thr or Coll; N=6 per group; **** $P < 0.0001$ versus ScrPept-NT. Calpain-1 isoforms were used as an indicator for calpain activation status. β actin levels were used as a loading control. (C) Representative images of thrombi formed on collagen coated surfaces under arteriolar shear (1,000 s^{-1}). Whole blood was pre-incubated with either ScrPept-NT or $^{62}\text{Pept-NT}$ (each 100 $\mu\text{g mL}^{-1}$). Percentage surface coverage (D), thrombus height (E) and thrombus volume (F) were calculated for whole blood treated with either ScrPept-NT (gray) or $^{62}\text{Pept-NT}$ (white; N=6 per group). (G) Representative images of thrombi at 5 min with CD61 stained donor platelets (magenta) and diffused calcein (cyan). (H) LOWESS curves of calcein diffusion over time with SEM error bars for ScrPept-NT (black) or $^{62}\text{Pept-NT}$ (red). (I) Summary data for calcein diffusion at 5 min. Data are representative of 4 independent experiments and scale bars = 10 μm . Data were analyzed by paired t test; * $P < 0.05$. Cx: connexin.

to be the main function of Cx62 cleavage.

To further assess the functional consequences of calpain cleavage, we directly assessed hemichannel and gap junction functions using a calcein diffusion assay. Previous studies have used calcein diffusion within pre-formed thrombi or single cells using fluorescence recovery after photobleaching (FRAP) technology or flow cytometry, respectively.^{16,18,36} We developed an alternative approach to measure temporal dynamics of calcein dye diffusion during thrombus formation (*Online Supplementary Figure S4*). This approach utilizes donor platelets that are co-stained with calcein dye and fluorescent CD61 antibodies to enable tracking of calcein diffusion over time. Thrombi were formed under arterial flow conditions (1,000s⁻¹) and calcein diffusion was found to initiate soon after platelets began to adhere to the collagen-coated surface. Under control conditions, calcein diffusion occurred at a steady rate across the five-minute time course (Figure 4G-I; *Online Supplementary Movie S1*). Pre-incubation of platelets with our decoy peptide significantly blunted calcein diffusion (Figure 4G-I; *Online Supplementary Movie S2*). These data indicate that calpain-1 influences the permeability through modification of the Cx62 pore diameter.

Calpain-1 regulation of Cx62 is dependent on intracellular Ca²⁺, cAMP and PP2A activity

We have demonstrated that PKA regulates Cx62 in a cAMP-independent manner.¹⁸ We therefore investigated other pathways that regulate PKA activity and their influence upon Cx62 cleavage. Elevation of cAMP leads to activation of PKA and downstream phosphorylation of the IP3 receptor, abrogating Ca²⁺ release.^{37,38} In the presence of PGI₂ immunoblot analysis shows increased levels of VASP phosphorylation at Ser¹⁵⁷, indicative of PKA activation (Figure 5A). PKA activation was associated reduced intracellular Ca²⁺ mobilization (Figure 5B), coinciding with a reduction of calpain-1 activation and protected against Cx62 cleavage (Figure 5A).

Protein phosphatase 2A (PP2A) is a negative regulator of PKA and is activated following platelet stimulation.³⁹ PP2A has been shown to disrupt PKA-dependent phosphorylation of neuronal Cx36 channels.⁴⁰ Platelet stimulation by collagen or thrombin increased PP2A phosphorylation, reduced VASP phosphorylation and was accompanied by cleavage of Cx62 (Figure 5C). Pre-incubating platelets with LB-100, a PP2A inhibitor, abrogated PKA activation, prevented calpain-1 activation and Cx62 remained intact (Figure 5C). Inhibition of PP2A also led to a significant reduction of intracellular Ca²⁺ mobilization, presumably through phosphorylation of the IP3 receptor (Figure 5D, E).

Finally, we determined whether direct inhibition of Cx62 by the mimetic peptide ⁶²Gap27 influenced calpain-mediated cleavage. Binding of ⁶²Gap27 to its target predicted site on the second extracellular loop of Cx62 inhibits channel activity and downregulates platelet function.¹⁸ Incubation

with the inhibitory peptide reduced levels of calpain activation and protected against calpain-1-mediated cleavage of Cx62 (Figure 6). The mechanism by which ⁶²Gap27 protects against cleavage is unclear but may be related to reduced Ca²⁺ flux, or by locking the channel in a closed conformation, rendering the calpain-1 cleavage site inaccessible.

Discussion

Connexins represent a universal mechanism for the regulation of intercellular communication between adjacent cells and tissues.^{11,41} The nature by which they are regulated is of fundamental importance and provides insights for the development of novel therapeutics. Calpain-mediated regulation of the intracellular domain of specific connexins has been highlighted previously.^{30,32} We report for the first time that the orphan connexin, Cx62, possesses a calpain-1 cleavage site that is situated within the first extracellular loop. Cleavage at this site is predicted to increase the size of the pore promoting intercellular communication and thrombus growth. Using platelets as a Cx62-expressing cellular model, we noted that proteolytic cleavage was mediated by calpain-1 and critically dependent upon elevation of intracellular Ca²⁺. Efforts to reduce Ca²⁺ flux through induction or modulation of the PKA signaling pathway abrogated calpain-1 activation and protected against cleavage of Cx62. Furthermore, selective inhibition of Cx62 by the peptide ⁶²Gap27 or decoy of active calpain by ⁶²Pept-NT prevented channel cleavage (Figure 7).

Studies in other cell types have identified connexins as substrates for calpain cleavage. Mouse liver Cx32, but not Cx26, is cleaved by both μ -calpain and m-calpain.²⁹ Cleavage occurs at an intracellular site within the C-terminus and phosphorylation of the channel by PKC, but not PKA, was shown to protect against protease activity.²⁹ Cx50 in lens fiber cells was also shown to undergo calpain cleavage of a C-terminal region, resulting in the removal of a 32 kDa portion of the channel.³⁰ We were therefore surprised to identify an extracellular calpain-1 cleavage site within the sequence of Cx62. Cleavage resulted in detection of a smaller fragment that was rapidly degraded following stimulation with collagen or thrombin. It is important to note that the 37 kDa band that was detected following stimulation (Figure 1) cannot be fully explained by the predicted extracellular calpain cleavage site, as the N-terminal anti-Cx62 antibody would be expected to detect a fragment of approximately 5 kDa, although we cannot exclude potential alternative cleavage sites. While none were detected using a bioinformatic approach, this may reflect a limitation of such experimental tools. It is therefore possible that the larger Cx62 fragment detected (Figure 1) represents intermediate products of protein degradation, mediated by calpain or other proteases, following initiation by an extracellular calpain-dependent cleavage event. We are therefore un-




Figure 5. Stimulation of PKA or inhibition of PP2A protects against calpain-1-mediated cleavage of Cx62. (A) The impact of PKA activation by prostacyclin (PGI₂; 280 nM, 5 minutes [min]) on levels of full-length Cx62, calpain-1 activation and VASP phosphorylation. Platelets that were resting (Unstim.) or stimulated by thrombin (Thr; 0.03 U mL⁻¹, 5 min) or collagen (Coll; 1 μg mL⁻¹, 5 min). β-actin was included as loading control and data are representative of 6 independent experiments. (B, D, E) Peak Ca²⁺ responses were monitored in response to stimulation by TRAP-6 (10 μM) or cross-linked collagen-related peptide (CRP-XL; 10 μg mL⁻¹). Where indicated platelets were pre-incubated with PGI₂ (280 nM, 5 min) or LB-100 (2.5 μM, 20 min) to establish contributions by PKA or PP2A, respectively. (C) The impact of PP2A inhibition by LB-100 (2.5 μM, 20 minutes) on levels of full-length Cx62, calpain-1 activation, VASP phosphorylation and PP2A phosphorylation. Platelets that were resting (Unstim.) or stimulated by thrombin (Thr; 0.03 U mL⁻¹, 5 min) or collagen (Coll; 1 μg mL⁻¹, 5 min). β-actin was included as loading control and data are representative of 7 independent experiments. Data are representative of 4 independent experiments. Statistical significance was determined by ANOVA. Not significant (NS), *, ** or *** denote $P > 0.05$, $P < 0.05$, $P < 0.01$ or $P < 0.001$, respectively. Cx: connexin.

able to confirm that the DEQSAFACNT|RQPG sequence is the definitive site that mediates or initiates Cx62 cleavage, pore dilation and protein degradation. Our modeling data (Figure 3) highlight that Cx62 is likely to be cleaved in step-wise manner, although the functional consequences of this remain to be determined. Surprisingly, incubation with recombinant calpain did not result in Cx62 cleavage of resting platelets. This may be explained by low levels of Cx62 on the surface of resting platelets, which we have previously shown.¹⁸ Alternatively, this may be explained by the calpain site being inaccessible in its closed conformation. Given that the calpain decoy peptide ⁶²Pept-NT is not cell permeable, our data support calpain-1-mediated cleavage at an extracellular site.

Calpain-1 release from cells has been reported from a variety of cells, including platelets.^{32–35} For example, extracellular calpain-1 has been implicated in vascular repair in a model of glomerulonephritis.³² The mechanism by which calpain-1 is released from cells is debated. Whilst release from apoptotic cells is a likely source, there is evidence also for active secretion from intact cells, such as lymphocytes, chondrocytes and endothelial cells.^{33,42} Calpain-1 has been detected within platelet-derived extracellular vesicles.³⁵ Calpain-1 released through this mechanism was shown to cleave PAR1 on vascular endothelial cells, stimulating synthesis of pro-inflammatory TNF- α . An alternative route for calpain-1 release may be through ATP-binding cassette transporters (i.e., ABCA1), which have been reported in human and mouse lymphocytes.⁴³ Platelets express ABCA1 and deletion of these transporters has been shown to reduce platelet reactivity to collagen and thrombin and down-regulated thromboxane A2 synthesis.⁴⁴ Whilst the authors state that this is likely due to altered lipid conversion in the absence of ABCA1, it is also possible that this deletion impacts calpain-1 release. Further studies are required to evaluate the precise mechanism(s) for calpain-1 release from activated platelets.

The functional role of calpain-1-dependent cleavage of connexin proteins remains unclear. Given that other connexin channels have a relatively short membrane half-life of a few hours, it is possible that calpain cleavage serves as a way to regulate Cx62 channel turnover.^{29,41} An alternative prospect is that cleavage of Cx62 by calpain-1 is required to facilitate irreversible transition to an additional open-state. In the absence of single channel recordings for Cx62, we do not know the open probability and to what extent calpain-1 influences permeability of specific ions. Pannexin-1 is structurally-related to connexins and has been shown to possess a caspase cleavage site within its intracellular C-terminus.^{45,46} Cryo-EM modeling shows that caspase cleavage removes an auto-inhibitory domain, leading to enhanced channel permeability and release of ATP.⁴⁷ Our modeling of Cx62 cleavage by calpain-1 suggests that similar regulatory mechanisms may be at play. Cleavage increases the minimum pore diameter from 12.5 Å to 29.5 Å, which




Figure 6. ⁶²Gap27 limits calpain-1 activation and Cx62 cleavage.

Effect of the selective Cx62 mimetic peptide inhibitor ⁶²Gap27 upon channel cleavage. Platelets were pre-incubated with either Scr⁶²Gap27 or ⁶²Gap27 (25 μ g mL⁻¹, 5 minutes [min]) and stimulated by thrombin (Thr; 0.03 U mL⁻¹, 5 min) or collagen (Coll; 1 μ g mL⁻¹, 5 min). Data are representative of 3 independent experiments and were analyzed by one-way ANOVA. Not significant (NS) and *** denote $P > 0.05$ and $P < 0.001$, respectively. Cx: connexin.

would increase permeability to ATP and other molecules (e.g., micro RNA, glucose and IP3). Cx62 cleavage by calpain may also serve to stabilize the channel in an open state, which facilitates recruitment of platelets into a thrombus and/or coordination of signaling events between platelets and the endothelium.

Our study highlights differences between platelet aggregation responses and the properties of thrombi formed *in vitro*. We show that aggregation in response to collagen or thrombin is not reliant upon Cx62 cleavage. However, the decoy peptide had mixed effects on thrombus formation, whereby surface coverage was unchanged but overall height and volume decreased. This difference likely relates to a static *versus* aqueous platelet agonists and the increased shear forces experienced by thrombi in whole blood assays. Calpain-deficient mice have reduced thrombus formation⁴⁸ and attenuated procoagulant activity.⁴⁹ We therefore conclude that these differences may relate to altered stability of platelet-platelet interaction in the more physiologically relevant thrombus formation assay.

We previously demonstrated that selective inhibition of Cx62 by ⁶²Gap27 attenuates platelet activation responses through reduction hemichannel and gap junction function.¹⁸ Binding of this peptide to Cx62 led to cAMP-independent




Figure 7. Schematic for the proposed regulation of calpain-1-dependent cleavage of platelet Cx62. The binding of platelet agonists thrombin or collagen to their receptors activate phospholipase C (PLC) β and γ isoforms, respectively. PLC triggers Ca^{2+} mobilization pathways, increasing cytosolic Ca^{2+} , inactivation of protein kinase A (PKA) by protein phosphatase 2A (PP2A) and release of granular contents. Calpain-1 may be released or secreted from the cytosol where it will be activated by plasma Ca^{2+} (2 mM). Calpain-1 is then able to dock to its cleavage site on the first extracellular loop of Cx62, facilitating transition to an irreversible open state. Chelation of Ca^{2+} by EGTA or BAPTA-AM prevented calpain-1 activation and protected against Cx62 cleavage. Furthermore, activation of PKA by incubation with prostaglandin I_2 (PGI_2) or inhibition of PP2A by LB-100, prevented Ca^{2+} mobilization and cleavage of Cx62. Cartoon created using Biorender (www.biorender.com). Cx: connexin.

activation of PKA, which is inhibitory in platelets.¹⁸ Platelets incubated with $^{62}\text{Gap27}$ were protected from calpain-1-mediated cleavage. Notably, the binding sites for calpain-1 and $^{62}\text{Gap27}$ reside within the first and second extracellular loops, respectively. The protective mechanism for the $^{62}\text{Gap27}$ peptide is unclear but may relate to $^{62}\text{Gap27}$ locking the channel in a closed conformation or disruption of calpain-1 binding by the peptide. Whilst the precise mechanisms by which Gap27 peptides inhibit connexins remain unclear, there is strong evidence that these peptides attach to, and are retained, at the extracellular face of the channel and their binding rapidly reduces the pore diameter.¹¹ We hypothesize that Cx62 channel activation is a pre-requisite to calpain-1-mediated cleavage and that this serves as a regulatory mechanism to protect against the action of calpains that have been released from other cells. In conclusion, we propose that agonist-evoked elevation of intraplatelet Ca^{2+} leads to the activation of Cx62 and release of calpain-1 from the cytosol, where it will be exposed to Ca^{2+} (2 mM) in the plasma (Figure 7). Subsequent interactions between calpain-1 and its substrate promotes further conformational change of Cx62. This presumably irreversible activation state facilitates increased intercellular communication through hemichannels and gap junctions. Targeting calpain-1 cleavage of Cx62 may represent a

mechanism to downregulate the response to injury in the context of arterial thrombosis. Our findings suggest a novel extracellular role for calpain-1 in the regulation of connexin 62 structure and function. Further studies are therefore justified to explore the impact of this mechanism on other cell types and tissues in the context of health and disease.

Disclosures

No conflicts of interest to disclose.

Contributions

KAT, AE, TLH and SP performed experiments. KAT, AE, and JMG critically analyzed the data. KAT, AE, RA, CEH, LJM and JMG wrote and edited the manuscript. RA and LJM directed the modeling studies. KAT, AE and JMG designed the study.

Funding

This work was supported by British Heart Foundation Project Grants PG/17/76/33082 to JMG and PG/22/10965 to KAT, and the Biotechnology and Biological Sciences Research Council (BBSRC) BB/T018496/1 to LJM and RA.

Data-sharing statement

Data are available upon request.

References

- Coppinger JA, Cagney G, Toomey S, et al. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. *Blood*. 2004;103(6):2096-2104.
- Golebiewska EM, Poole AW. Platelet secretion: from haemostasis to wound healing and beyond. *Blood Rev*. 2015;29(3):153-162.
- Whiteheart SW. Platelet granules: surprise packages. *Blood*. 2011;118(5):1190-1191.
- Smyth SS, McEver RP, Weyrich AS, et al. Platelet functions beyond hemostasis. *J Thromb Haemost*. 2009;7(11):1759-1766.
- Mandel J, Casari M, Stepanyan M, Martyanov A, Deppermann C. Beyond hemostasis: platelet innate immune interactions and thromboinflammation. *Int J Mol Sci*. 2022;23(7):3868.
- Rayes J, Bourne JH, Brill A, Watson SP. The dual role of platelet-innate immune cell interactions in thrombo-inflammation. *Res Pract Thromb Haemost*. 2020;4(1):23-35.
- Molica F, Figueroa XF, Kwak BR, Isakson BE, Gibbins JM. Connexins and pannexins in vascular function and disease. *Int J Mol Sci*. 2018;19(6):1663.
- Kutova OM, Pospelov AD, Balalaeva IV. The multifaceted role of connexins in tumor microenvironment initiation and maintenance. *Biology (Basel)*. 2023;12(2):204.
- Vicario N, Parenti R. Connexins signatures of the neurovascular unit and their physio-pathological functions. *Int J Mol Sci*. 2022;23(17):9510.
- Laird DW, Lampe PD. Therapeutic strategies targeting connexins. *Nat Rev Drug Discov*. 2018;17(12):905-921.
- Evans WH, Bultynck G, Leybaert L. Manipulating connexin communication channels: use of peptidomimetics and the translational outputs. *J Membr Biol*. 2012;245(8):437-449.
- Pogoda K, Kameritsch P, Mannell H, Pohl U. Connexins in the control of vasomotor function. *Acta Physiol (Oxf)*. 2019;225(1):e13108.
- Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon channels. *Nat Rev Mol Cell Biol*. 2003;4(4):285-294.
- John S, Cesario D, Weiss JN. Gap junctional hemichannels in the heart. *Acta Physiol Scand*. 2003;179(1):23-31.
- Angelillo-Scherrer A, Fontana P, Burnier L, et al. Connexin 37 limits thrombus propensity by downregulating platelet reactivity. *Circulation*. 2011;124(8):930-939.
- Vaiyapuri S, Jones CI, Sasikumar P, et al. Gap junctions and connexin hemichannels underpin hemostasis and thrombosis. *Circulation*. 2012;125(20):2479-2491.
- Vaiyapuri S, Moraes LA, Sage T, et al. Connexin40 regulates platelet function. *Nat Commun*. 2013;4(1):2564.
- Sahli KA, Flora GD, Sasikumar P, et al. Structural, functional, and mechanistic insights uncover the fundamental role of orphan connexin-62 in platelets. *Blood*. 2021;137(6):830-843.
- Aasen T, Johnstone S, Vidal-Brime L, Lynn KS, Koval M. Connexins: synthesis, post-translational modifications, and trafficking in health and disease. *Int J Mol Sci*. 2018;19(5):1296.
- Unsworth AJ, Flora GD, Sasikumar P, et al. RXR Ligands negatively regulate thrombosis and hemostasis. *Arterioscler Thromb Vasc Biol*. 2017;37(5):812-822.
- McGuffin LJ, Adiyaman R, Maghrabi AHA, et al. IntFOLD: an integrated web resource for high performance protein structure and function prediction. *Nucleic Acids Res*. 2019;47(W1):W408-W413.
- Grosdidier A, Zoete V, Michielin O. SwissDock, a protein-small molecule docking web service based on EADock DSS. *Nucleic Acids Res*. 2011;39(Web Server issue):W270-277.
- Jumper J, Evans R, Pritzel A, et al. Highly accurate protein structure prediction with AlphaFold. *Nature*. 2021;596(7873):583-589.
- McGuffin LJ, Edmunds NS, Genc AG, Alharbi SMA, Salehe BR, Adiyaman R. Prediction of protein structures, functions and interactions using the IntFOLD7, MultiFOLD and ModFOLDdock servers. *Nucleic Acids Res*. 2023;51(W1):W274-W280.
- Jones DT, Cozzetto D. DISOPRED3: precise disordered region predictions with annotated protein-binding activity. *Bioinformatics*. 2015;31(6):857-863.
- Unwin PN, Ennis PD. Two configurations of a channel-forming membrane protein. *Nature*. 1984;307(5952):609-613.
- Ishii H, Umeda F, Hashimoto T, Nawata H. Increased intracellular calcium mobilization in platelets from patients with type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia*. 1991;34(5):332-336.
- Varga-Szabo D, Braun A, Nieswandt B. Calcium signaling in platelets. *J Thromb Haemost*. 2009;7(7):1057-1066.
- Elvira M, Diez JA, Wang KK, Villalobo A. Phosphorylation of connexin-32 by protein kinase C prevents its proteolysis by mu-calpain and m-calpain. *J Biol Chem*. 1993;268(19):14294-14300.
- Lin JS, Fitzgerald S, Dong Y, Knight C, Donaldson P, Kistler J. Processing of the gap junction protein connexin50 in the ocular lens is accomplished by calpain. *Eur J Cell Biol*. 1997;73(2):141-149.
- Amici DR, Pinal-Fernandez I, Mazala DA, et al. Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis. *Acta Neuropathol Commun*. 2017;5(1):24.
- Letavernier B, Zafrani L, Nassar D, et al. Calpains contribute to vascular repair in rapidly progressive form of glomerulonephritis: potential role of their externalization. *Arterioscler Thromb Vasc Biol*. 2012;32(2):335-342.
- Letavernier E, Zafrani L, Perez J, Letavernier B, Haymann JP, Baud L. The role of calpains in myocardial remodelling and heart failure. *Cardiovasc Res*. 2012;96(1):38-45.
- Miyazaki T, Akasu R, Miyazaki A. Calpain proteolytic systems counteract endothelial cell adaptation to inflammatory environments. *Inflamm Regen*. 2020;40:5.
- Kyselova A, Elgheznavy A, Wittig I, et al. Platelet-derived calpain cleaves the endothelial protease-activated receptor 1 to induce vascular inflammation in diabetes. *Basic Res Cardiol*. 2020;115(6):75.
- Taylor KA, Wright JR, Vial C, Evans RJ, Mahaut-Smith MP. Amplification of human platelet activation by surface pannexin-1 channels. *J Thromb Haemost*. 2014;12(6):987-998.
- Bugrim AE. Regulation of Ca²⁺ release by cAMP-dependent protein kinase. A mechanism for agonist-specific calcium signaling? *Cell Calcium*. 1999;25(3):219-226.
- Shiraha H, Glading A, Chou J, Jia Z, Wells A. Activation of m-calpain (calpain II) by epidermal growth factor is limited by protein kinase A phosphorylation of m-calpain. *Mol Cell Biol*. 2002;22(8):2716-2727.
- Wadzinski BE, Wheat WH, Jaspers S, et al. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. *Mol Cell Biol*. 1993;13(5):2822-2834.

40. Kothmann WW, Massey SC, O'Brien J. Dopamine-stimulated dephosphorylation of connexin 36 mediates All amacrine cell uncoupling. *J Neurosci.* 2009;29(47):14903-14911.
41. Laird DW. Life cycle of connexins in health and disease. *Biochem J.* 2006;394(Pt 3):527-543.
42. Deshpande RV, Goust JM, Chakrabarti AK, Barbosa E, Hogan EL, Banik NL. Calpain expression in lymphoid cells. Increased mRNA and protein levels after cell activation. *J Biol Chem.* 1995;270(6):2497-2505.
43. Perez J, Dansou B, Herve R, et al. Calpains released by T lymphocytes cleave TLR2 to control IL-17 expression. *J Immunol.* 2016;196(1):168-181.
44. Lhermusier T, Severin S, Van Rothen J, et al. ATP-binding cassette transporter 1 (ABCA1) deficiency decreases platelet reactivity and reduces thromboxane A2 production independently of hematopoietic ABCA1. *J Thromb Haemost.* 2016;14(3):585-595.
45. Sandilos JK, Chiu YH, Chekeni FB, et al. Pannexin 1, an ATP release channel, is activated by caspase cleavage of its pore-associated C-terminal autoinhibitory region. *J Biol Chem.* 2012;287(14):11303-11311.
46. Chekeni FB, Elliott MR, Sandilos JK, et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. *Nature.* 2010;467(7317):863-867.
47. Ruan Z, Orozco IJ, Du J, Lu W. Structures of human pannexin 1 reveal ion pathways and mechanism of gating. *Nature.* 2020;584(7822):646-651.
48. Mithila F, Schwake C, Fang C, et al. Calpain-1 inhibition attenuates in vivo thrombosis in a humanized model of sickle cell disease. *Thromb Res.* 2022;211:123-126.
49. Mattheij NJ, Gilio K, van Kruchten R, et al. Dual mechanism of integrin alphaIIb beta3 closure in procoagulant platelets. *J Biol Chem.* 2013;288(19):13325-13336.